198 related articles for article (PubMed ID: 1355853)
1. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Juliusson G; Elmhorn-Rosenborg A; Liliemark J
N Engl J Med; 1992 Oct; 327(15):1056-61. PubMed ID: 1355853
[TBL] [Abstract][Full Text] [Related]
2. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
O'Brien S; Kantarjian H; Estey E; Koller C; Robertson B; Beran M; Andreeff M; Pierce S; Keating M
N Engl J Med; 1994 Feb; 330(5):319-22. PubMed ID: 7904047
[TBL] [Abstract][Full Text] [Related]
3. New purine analogues for the treatment of chronic B-cell malignancies.
Gribbin TE
Henry Ford Hosp Med J; 1991; 39(2):98-102. PubMed ID: 1679757
[TBL] [Abstract][Full Text] [Related]
4. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.
Piro LD; Carrera CJ; Carson DA; Beutler E
N Engl J Med; 1990 Apr; 322(16):1117-21. PubMed ID: 1969613
[TBL] [Abstract][Full Text] [Related]
5. Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia.
Med Lett Drugs Ther; 1992 Sep; 34(879):89-90. PubMed ID: 1355592
[No Abstract] [Full Text] [Related]
6. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
7. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Saven A; Lemon RH; Piro LD
N Engl J Med; 1993 Mar; 328(11):812-3. PubMed ID: 8094889
[No Abstract] [Full Text] [Related]
8. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Delannoy A; Hanique G; Ferrant A
N Engl J Med; 1993 Mar; 328(11):812; author reply 813. PubMed ID: 8094888
[No Abstract] [Full Text] [Related]
9. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
Varga F; Lehoczky D; Demeter J
Orv Hetil; 1999 Aug; 140(31):1731-5. PubMed ID: 10463032
[TBL] [Abstract][Full Text] [Related]
10. Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues.
Larsen CR; Hansen PB; Clausen NT
Am J Hematol; 2002 May; 70(1):48-50. PubMed ID: 11994981
[TBL] [Abstract][Full Text] [Related]
11. [Treatment with fludarabine of chronic refractory lymphoid leukemia].
Herrero M; Cabrera JR; Briz M; Forés R; Díez JL; Regidor C; Sanjuán I; Fernández MN
Sangre (Barc); 1995 Apr; 40(2):115-9. PubMed ID: 7784940
[TBL] [Abstract][Full Text] [Related]
12. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
Perkins JG; Flynn JM; Howard RS; Byrd JC
Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
[TBL] [Abstract][Full Text] [Related]
16. [Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
Pawelski S
Acta Haematol Pol; 1995; 26(3):263-8. PubMed ID: 8525771
[TBL] [Abstract][Full Text] [Related]
17. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
18. 2-Chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine?
Schirmer M; Michlmayr G; Geisen F; Konwalinka G
Leukemia; 1996 Jul; 10(7):1253-4. PubMed ID: 8684013
[No Abstract] [Full Text] [Related]
19. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
[TBL] [Abstract][Full Text] [Related]
20. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
O'Brien S; Kantarjian H; Beran M; Robertson LE; Koller C; Lerner S; Keating MJ
Blood; 1995 Aug; 86(4):1298-300. PubMed ID: 7632936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]